Lupin has secured US FDA approval for their Dapagliflozin tablets, which are equivalent to Farxiga. This move allows Lupin to enter the substantial U.S. anti-diabetic market, demonstrating their research and development prowess.
Lupin Ltd has experienced a fifth straight day of decline, indicating persistent market weakness continues to affect the company's stock performance.
Pharmaceutical companies like Dr. Reddy's and Lupin in India are integrating Artificial Intelligence (AI) into their operations for drug discovery, trials, and manufacturing. A discussion on AI's influence within the pharmaceutical sector was held with experts from PwC India, Dr. Reddy's, and Lupin by The Economic Times.
Despite the broader market sell-off, Lupin, Sun Pharma, Torrent Pharma, CCL Products, and Karnataka Bank show remarkable resilience due to robust fundamentals like steady growth, strong pipelines, and strategic moves. Their performance suggests a potential for long-term leadership.
Lupin has successfully acquired VISUfarma, a European leader in ophthalmology, boosting its presence in key markets such as Italy, the UK, Spain, Germany, and France. This move is expected to broaden Lupin's therapeutic portfolio and solidify its position in Europe.
Lupin's subsidiary, Nanomi B.V., has announced the acquisition of VISUfarma B.V., set to take effect from April 1, 2026. This move expands Lupin's pharmaceutical portfolio and strengthens its position in the industry.
Lupin's Dutch subsidiary, Nanomi B.V., has announced plans to acquire a significant stake in MPPI, aiming to strengthen and expand its pharmaceutical footprint in the Philippines market.
Indian Oil Corporation Limited (IOCL) achieved all-time highs in both crude and pipeline throughput during the fiscal year 2025-2026, with crude reaching 75.4 MMT and pipelines at 105.3 MMT. Lupin's subsidiary is planning to acquire a 43.4% stake in the Philippines' MPPI for approximately $39.6 million, while auto and banking stocks remain under scrutiny.
Lupin has secured a tentative approval from the US FDA for Sugammadex Injection, which is biologically equivalent to Merck's Bridion. The approval covers two strengths: 200mg/2mL and 500mg/5mL vials.
Lupin receives temporary approval from the FDA for Sugammadex injections, a drug that counteracts muscle paralysis induced by rocuronium or vecuronium during surgeries.
Lupin has increased its control over MultiCare Pharmaceuticals Philippines (MPPI) significantly, purchasing 2.8 million shares to now own 56.3% of the company, up from the previous 51%. This move strengthens Lupin's position in the Philippine pharmaceutical market.
Lupin's subsidiary, MPPI, purchased 2.8 million shares, significantly increasing Nanomi's holding in MPPI to approximately 56.3%. This move didn't involve Nanimi directly, with MPPI generating a turnover of PHP 2.09 billion.